0001209191-20-007695.txt : 20200207
0001209191-20-007695.hdr.sgml : 20200207
20200207185424
ACCESSION NUMBER: 0001209191-20-007695
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gano Kyle
CENTRAL INDEX KEY: 0001567160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 20588870
MAIL ADDRESS:
STREET 1: NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-05
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001567160
Gano Kyle
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Business Development Off
Common Stock
2020-02-05
4
S
0
1013
103.0072
D
87204
D
Common Stock
2020-02-05
4
S
0
703
103.0347
D
87838
D
Common Stock
2020-02-05
4
S
0
1974
103.0812
D
89614
D
Common Stock
2020-02-06
4
S
0
1000
101.413
D
90514
D
Stock Option
102.90
2020-02-06
4
A
0
76683
0.00
A
2030-02-06
Common Stock
76683
76683
D
Restricted Stock Unit
2020-02-06
4
A
0
12148
0.00
A
Common Stock
12148
12148
D
Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.16 to $105.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Includes a total of 459 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 312 shares on February 28, 2019 and 147 shares on August 30, 2019.
Sale of 703 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 1,974 shares of common stock issued upon vesting of 3,750 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,776) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.86 to $105.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 1,000 shares of common stock issued upon vesting of 1,900 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (900) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.73 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024.
/s/ Darin Lippoldt, Attorney-in-Fact
2020-02-07